| |
Improve care access with data and dashboards that identify and prioritize healthcare disparities across the patient journey. Learn how you can quickly surface health equity statistics, reporting access to care, adherence rates, and SDOH drivers. 
|
|
| By Annalee Armstrong The overall deal flow in biopharma tapered off in 2023 but the big companies sure know what they want (what they really, really want), according to a new report from J.P. Morgan. |
|
|
|
By Angus Liu Nearly all top cancer drugmakers have struck deals in the sizzling antibody-drug conjugate field—but not Novartis. On Monday, the Swiss pharma’s CEO Vas Narasimhan explained how he's resisted the temptation. |
By Annalee Armstrong Eli Lilly CEO David Ricks, speaking to the slow and steady progress that brought tirzepitide to the world, says the Indianapolis pharma is now ready to open up the chocolate factory. |
By Fraiser Kansteiner Pfizer knows it had a bad year in 2023. Speaking to reporters at the 2024 J.P. Morgan Healthcare Conference on Monday, the company’s CEO, Albert Bourla, spoke bluntly about the hits the company took, and he acknowledged the underperformance of certain key launches. |
By Conor Hale 2023 was a banner year for Dexcom. Not only did it undertake a new major product launch, but it received the largest expansion of insurance coverage in the company’s history. And it’s got the receipts to show for it. |
By Angus Liu While some Merck & Co. investors may still get the heebie-jeebies when thinking about Keytruda’s patent cliff in 2028, but the company’s CEO Rob Davis now thinks “it’s just another year.” |
By Max Bayer Just more than two years after launching within Alphabet, Isomorphic has inked two large pharma deals with Eli Lilly and Novartis with nearly $3 billion in combined deal value. |
By Nick Paul Taylor Eli Lilly is taking a stand against the use of its blockbuster GLP-1 receptor agonist for “cosmetic weight loss.” In an open letter, the drugmaker came out against the use of Mounjaro and Zepbound for cosmetic weight loss after becoming “aware of certain practices relating” to the medicines. |
By Helen Floersh New research findings in mice suggest that drugs that inhibit a key protein involved in the pain response, such as the anti-epileptic and bipolar disorder drug carbamazepine, may be effective at slowing the progression of osteoarthritis. |
By Angus Liu Amid a manufacturing expansion spree for Pluvicto, Novartis is initiating a new commercial radiotherapy facility billed as “the company’s largest and most advanced in the world." |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," Fierce Biotech staff writer Gabrielle Masson and senior editor Annalee Armstrong look back at the year in biotech, which was defined by massive layoffs across the industry. They also discuss their favorite stories of the year, including an appearance from a popstar whose reputation precedes her. |
|
|---|
|
|
|
Wednesday, January 24, 2024 | 2:00pm ET / 11:00am PT Join our webinar to hear experts how digital collection of patient-reported outcomes (PROs) can lay the foundation for advancing health equity, which methods can ensure that PROs are relevant for diverse populations, and what challenges and opportunities still lie ahead. 
|
|
Whitepaper Discover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient. Sponsored by: Catalent |
eBook This e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development.
Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Any EHR provider delivering a quality point-of-care marketing solution should be able to answer these seven questions. Sponsored by: Veradigm |
Whitepaper The road to digital health innovation is exciting but complex and requires thoughtful navigation; this whitepaper serves as your guide through this process. Sponsored by: S3 Connected Health |
| |
|
